All News
MMWR: Vaccination and Multisystem Inflammatory Syndrome in Children
d
CDC
Multisystem inflammatory syndrome in children (MIS-C) is a rare but serious condition typically occurring 2–6 weeks after SARS-CoV-2 infection and characterized by fever and multiorgan involvement. The current MMWR report shows that MIS-C case numbers have decreased by 98% since 2021.
Read Article
US Trends in RA DMARD Use 2017-2021
A trend analysis of DMARDs shows that only half of rheumatoid arthritis (RA) patients are taking DMARDs, and that the COVID-19 pandemic substantially affected DMARD use. Despite numerous DMARD advances and evolving treatment guidelines since 1990, older therapies are still commonly used and the latest agents make up a small percentage of overall DMARD use.
Read Article
Again, a High Mortality with Depression and RA
Last week we reported on a Korean study showing a 66% elevated mortality risk in RA patients (n=38,487) with depression.
Read Article
9 Facts about Leflunomide
Medscape has published an informative review of leflunomide, drawn from Dr. Eric Ruderman’s recent lecture on the subject at the February RWCS meeting in Maui.
Read Article
SLE & remission on hemodyalysis (HD)? Cohort of 137 pts starting HD & the # off SLE Rx increased w/ time: 67% (HD start), 76.0% (1st Yr), 83% at 3 yrs (less w/ younger). Lupes flares most in 1st yr of HD; @12 mos 52% minor and 12% had severe flares. https://t.co/8N7CJWkIUY https://t.co/48eOclzrJH
Dr. John Cush RheumNow ( View Tweet)
Japanese study of 672 autoimmune pts on TNFi & tocilizumab - 1.6% (n=9) developed non-tuberculous Mycobacteria (NTM) infx post biologics. 2 disseminated NTM, 2 died. NTM pts had higher mortality [(22% vs 2.6%) & took more steroid (17 vs 3 mg, P=0.004).https://t.co/cLqt3FSzBk https://t.co/eD84WPZyuq
Links:
Dr. John Cush RheumNow ( View Tweet)
Long-term safety of Ixekizumab (IXE) - 26 RCTs (22k PYs) in PSO, PsA, AS & nr-axSpA
- nasopharyngitis most common AE; AEs did not incr over time
- D/C from AE 3-5/100Pys
- ISRs: 5.9-11.6/100PYs
- Candida 1.2-2/100PYs
- IBD: 0.1 PsO - 0.8/100PY for axSpA
https://t.co/nOoCE3VOxD https://t.co/F4gP1yR1Je
Dr. John Cush RheumNow ( View Tweet)
Dutch study of 586 RA pts on bDMARDs found more nonserious infections (NSIE) (77/100PYs) than serious infx (SIE)(1.3/100Pys). Upper respiratory tract infections were most frequent with recurrence rate that remained stable over time https://t.co/zwELL2yevG https://t.co/GLbidGvjp3
Dr. John Cush RheumNow ( View Tweet)
DANBIO #RA registry study: in 21,982 Rx starts (96K PtYrs) saw 1423 cancers w/ no overall increase in cancer risk with tocilizumab, sarilumab, abatacept, or rituximab (HRs from 0.7–1.1). No diff betw ABA vs TNFi (HR 1.41) nor HEME CA RTX vs TNFi (HR 0.09) https://t.co/mIEqALnnwI https://t.co/N1v3TzuBGm
Dr. John Cush RheumNow ( View Tweet)
Chinese SLE registry study of 350 SLE-TP (low plts) pts - 55% were aPL Ab+ (who had lower Plts @baseline (61K vs 76k). aPL+ SLE-TP pts w/ higher relapse rate (58% vs. 44%, P=0.009) & lower complete response rate. > more aPLs--> increased relapse rates https://t.co/Mb2YhsniVJ https://t.co/92QRWICcB4
Dr. John Cush RheumNow ( View Tweet)
JAMA Review of DMARD Use in Rheumatoid Arthritis
JAMA has reviewed the "2022 EULAR Recommendations for the Management of Rheumatoid Arthritis With Synthetic and Biological Disease-Modifying Antirheumatic Drugs".
https://t.co/pJLriraWqq https://t.co/JElMzDyeMs
Dr. John Cush RheumNow ( View Tweet)
COX-2 (on the left) have lower ulcer risk than COX-1 (to the right) NSAIDs. @BCryer https://t.co/Xfm7xJkvzd
Dr. John Cush RheumNow ( View Tweet)
High risk pts on NSAIDs need prophylaxis!! @bcryer https://t.co/NAnHtkTNvL
Dr. John Cush RheumNow ( View Tweet)
Endoscopy and Worry are indicated in the face of DYSPEPSIA and any of these: @BCryer https://t.co/6TabKhiLPO
Dr. John Cush RheumNow ( View Tweet)
Testing for H. Pylori. Serologic tests are OK but after Rx eradication, 25% of pts will remain positive for H. Pylori. @BCryer
Dr. John Cush RheumNow ( View Tweet)
Multiple Rx options to treat H. Pylori - Dr. Cryer recs regimens of 14ds; top line w/ bismuth is most recommended. (most effective is the one the patient will actualy take!) @BCryer https://t.co/f6836Ga1Fz
Dr. John Cush RheumNow ( View Tweet)
H. Pylori is usually acquired during childhood, remains dormant until activated years later. Is assoc w/ PUD and gastric cancer, not dyspepsia. Baylor Univ Grand Round By Dr. Byron Cryer @BCryer https://t.co/KXZfigVYX9
Dr. John Cush RheumNow ( View Tweet)
Mixed Long-term Effects of Calcium and Vitamin D in Postmenopausal Women
https://t.co/u2cf5hmTAE https://t.co/A4kdwG6eRm
Dr. John Cush RheumNow ( View Tweet)
JAK-pot: 46913 Rx courses on JAKi, TNFi, other MOA. Rx D/Cs for AEs:
- TNFi = JAKi (HR 1.0)
- Other MOA > JAKi (HR 1.11)
- TNFi < tofacitinib (0.81)
- TNFi > baricitinib (1.15)
- TNFi < JAKi; if >65yrs w/ CV risk (0.79) https://t.co/N5XnPjxAXO https://t.co/AnoKM7fzM7
Dr. John Cush RheumNow ( View Tweet)
What do you know about monogenic and polygenic autoinflammatory diseases? Join Drs Liebowitz and Mehta as they review the challenges of these conditions. https://t.co/EqJRXSzrEs https://t.co/z5yuHDXUZ3
Links:
Dr. John Cush RheumNow ( View Tweet)
